Amgen (NASDAQ:AMGN) Stock Purchase Disclosed by Rep. David Taylor

Key Points

• Rep. David Taylor disclosed purchasing $1,001–$15,000 of Amgen shares on September 22 through his trust-linked 401(k) account.
• Amgen reported quarterly results above expectations, with EPS of $6.29 and revenue of $10.05 billion; revenue increased 9.5% year over year. The company also declared a quarterly dividend of $2.52 per share, representing a 2.5% yield.
• Analysts remain broadly cautious, with Amgen carrying a consensus “Hold” rating and an average price target of $385.25, while institutional investors own 76.5% of the company.

Representative David Taylor (Republican-Ohio) recently bought shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on October 1st, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on September 22nd. The trade occurred in the Representative's "DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) - DAVE" account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Marathon Petroleum NYSE: MPC on 9/22/2026.
• Purchased $1,001 - $15,000 in shares of Home Depot NYSE: HD on 9/22/2026.
• Purchased $1,001 - $15,000 in shares of Installed Building Products NYSE: IBP on 9/8/2026.
• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 9/8/2026.
• Sold $1,001 - $15,000 in shares of Amgen NASDAQ: AMGN on 8/26/2026.
• Sold $1,001 - $15,000 in shares of Vertex Pharmaceuticals NASDAQ: VRTX on 8/26/2026.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Fifth Third Bancorp NASDAQ: FITB on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of American Electric Power NASDAQ: AEP on 8/26/2026.

Amgen Stock Performance

Shares of AMGN opened at $403.04 on Friday. Amgen Inc. has a 1 year low of $288.00 and a 1 year high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The stock's fifty day moving average price is $410.72 and its two-hundred day moving average price is $370.33. The firm has a market cap of $217.90 billion, a PE ratio of 25.05, a PEG ratio of 2.94 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same period last year, the firm earned $6.02 EPS. The business's quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts forecast that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were given a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.5%. Amgen's dividend payout ratio is presently 62.65%.

Institutional Trading of Amgen

Hedge funds have recently bought and sold shares of the business. Baird Financial Group Inc. raised its holdings in Amgen by 1.6% during the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company's stock worth $123,057,000 after purchasing an additional 5,496 shares during the last quarter. MW Advisory LLC bought a new position in Amgen during the 2nd quarter valued at $1,054,000. Integrated Advisors Network LLC boosted its stake in Amgen by 50.5% in the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company's stock valued at $6,664,000 after acquiring an additional 6,356 shares during the period. KBC Group NV grew its holdings in Amgen by 51.7% in the 2nd quarter. KBC Group NV now owns 382,676 shares of the medical research company's stock worth $138,574,000 after buying an additional 130,497 shares in the last quarter. Finally, Nilsine Partners LLC acquired a new stake in shares of Amgen in the second quarter valued at $3,329,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares of the company's stock, valued at $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 6,222 shares of company stock valued at $2,540,926. Insiders own 0.85% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on AMGN. Scotiabank lifted their price target on Amgen from $450.00 to $500.00 and gave the stock an "outperform" rating in a research note on Monday. Jefferies Financial Group restated a "hold" rating and issued a $410.00 target price on shares of Amgen in a research note on Wednesday, September 23rd. BMO Capital Markets cut shares of Amgen from an "outperform" rating to a "market perform" rating and set a $450.00 target price for the company. in a report on Tuesday, September 8th. Wells Fargo & Company increased their target price on Amgen from $400.00 to $435.00 and gave the company an "equal weight" rating in a report on Friday, September 4th. Finally, Barclays raised their price objective on shares of Amgen from $360.00 to $380.00 and gave the company an "equal weight" rating in a research report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $385.25.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio's 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Taylor (Republican Party) ran for election to the U.S. House to represent Ohio's 2nd Congressional District. He won in the general election on November 5, 2024. David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor's career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen's portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.